Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3%
of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as
obsessions, and feel compelled to perform repetitive behaviors, or compulsions. The only
medications proven effective for OCD are serotonin reuptake inhibitors (SRIs), but even with
SRI treatment, most patients continue to experience significant OCD symptoms, impaired
functioning, and diminished quality of life. Recent evidence suggest that a different
neurotransmitter, glutamate, may contribute to the symptoms in OCD. Medications that target
glutamate hold promise for ameliorating symptoms for those patients continuing to suffer from
OCD. In this study we are recruiting patients to receive the drug NPL-2003, which is thought
to modulate the neurotransmitter glutamate, added to whatever other OCD medications they are
taking in a 12-week open label study.